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BACKGROUND
Philadelphia chromosome–like acute lymphoblastic leukemia (Ph-like ALL) is char-
acterized by a gene-expression profile similar to that of BCR–ABL1–positive ALL, 
alterations of lymphoid transcription factor genes, and a poor outcome. The fre-
quency and spectrum of genetic alterations in Ph-like ALL and its responsiveness 
to tyrosine kinase inhibition are undefined, especially in adolescents and adults.
METHODS
We performed genomic profiling of 1725 patients with precursor B-cell ALL and 
detailed genomic analysis of 154 patients with Ph-like ALL. We examined the 
functional effects of fusion proteins and the efficacy of tyrosine kinase inhibitors 
in mouse pre-B cells and xenografts of human Ph-like ALL.
RESULTS
Ph-like ALL increased in frequency from 10% among children with standard-risk 
ALL to 27% among young adults with ALL and was associated with a poor outcome. 
Kinase-activating alterations were identified in 91% of patients with Ph-like ALL; 
rearrangements involving ABL1, ABL2, CRLF2, CSF1R, EPOR, JAK2, NTRK3, PDGFRB, 
PTK2B, TSLP, or TYK2 and sequence mutations involving FLT3, IL7R, or SH2B3 were 
most common. Expression of ABL1, ABL2, CSF1R, JAK2, and PDGFRB fusions re-
sulted in cytokine-independent proliferation and activation of phosphorylated STAT5. 
Cell lines and human leukemic cells expressing ABL1, ABL2, CSF1R, and PDGFRB 
fusions were sensitive in vitro to dasatinib, EPOR and JAK2 rearrangements were 
sensitive to ruxolitinib, and the ETV6–NTRK3 fusion was sensitive to crizotinib.
CONCLUSIONS
Ph-like ALL was found to be characterized by a range of genomic alterations that 
activate a limited number of signaling pathways, all of which may be amenable to 
inhibition with approved tyrosine kinase inhibitors. Trials identifying Ph-like ALL 
are needed to assess whether adding tyrosine kinase inhibitors to current therapy 
will improve the survival of patients with this type of leukemia. (Funded by the 
American Lebanese Syrian Associated Charities and others.)
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A cute lymphoblastic leukemia (ALL) is the most common childhood cancer and a major cause of illness and death in 
adults.1 ALL encompasses a number of distinct 
entities characterized by chromosomal rear-
rangements, structural variations, and sequence 
mutations that perturb lymphoid maturation, 
cell proliferation, cell-growth suppression, and 
epigenetic regulation.2 Our understanding of the 
genetic basis of ALL has been transformed by 
genomewide profiling studies that have identi-
fied multiple targets of recurring genetic altera-
tions and have defined new subtypes of ALL.
Childhood ALL is more commonly of B-cell 
than T-cell lineage and includes cases associated 
with hyperdiploidy, hypodiploidy, and chromo-
somal rearrangements resulting in chimeric fu-
sion genes, including ETV6–RUNX1, TCF3–PBX1, 
and BCR–ABL1, as well as rearrangements of MLL 
and CRLF2. As compared with younger children 
with ALL, adolescents and adults with ALL have 
inferior outcomes, partly because of the lower 
frequency of favorable genetic features such as 
ETV6–RUNX1 and hyperdiploidy, as well as the 
higher frequency of BCR–ABL13; however, the 
genetic basis of ALL in adolescents and adults is 
poorly defined.
One subtype of precursor B-cell ALL is BCR–
ABL1–like, or Philadelphia chromosome–like 
(Ph-like), ALL. Patients with Ph-like ALL do not 
have the BCR–ABL1 fusion protein expressed 
from the t(9;22)(q34;q11.2) Philadelphia chro-
mosome yet have a gene-expression profile 
similar to that of patients with BCR–ABL1 
ALL.4,5 Deletions or mutations of the lymphoid 
transcription factor gene IKZF1 (encoding Ikaros) 
are a hallmark of both BCR–ABL1–positive ALL 
and Ph-like ALL,4,6 and Ph-like ALL in children is 
associated with poor outcomes.4,5,7-10 Transcrip-
tome sequencing and whole-genome sequencing 
in 15 children with Ph-like ALL identified chro-
mosomal rearrangements or sequence muta-
tions deregulating cytokine receptor and tyro-
sine kinase genes in all 15.11 In addition, there 
have been recent reports of patients with refrac-
tory Ph-like ALL and the EBF1–PDGFRB fusion 
who have a remarkably good response to therapy 
with tyrosine kinase inhibitors.12,13 Because the 
full spectrum of kinase-activating genetic altera-
tions in Ph-like ALL, their effect on outcomes in 
adolescents and young adults, and their poten-
tial for therapeutic targeting are unknown, we 
performed a detailed genomic analysis of 1725 
children, adolescents, and young adults with pre-
cursor B-cell ALL.
Me thods
Study Design
We studied 2013 patients with precursor B-cell 
ALL, 1725 of whom had material available for 
microarray gene-expression profiling; 1589 of 
these 1725 patients had single-nucleotide-poly-
morphism microarray profiling performed. The 
cohort included 330 children with National Can-
cer Institute–classified, standard-risk precursor 
B-cell ALL (age range, 1 to 9 years; and periph-
eral-blood leukocyte count at diagnosis, <50,000 
per cubic millimeter), 853 children with high-risk 
precursor B-cell ALL (age range, 10 to 15 years; 
leukocyte count, ≥50,000 per cubic millimeter; 
or both), 374 adolescents (age range, 16 to 20 
years), and 168 young adults (age range, 21 to 
39 years) (Table S1 in Supplementary Appendix 
1 and Fig. S1 in Supplementary Appendix 2, avail-
able with the full text of this article at NEJM.org). 
There were few significant differences in the clini-
cal features of patients with gene-expression 
profiling data available and those without such 
data available (Table S2 in Supplementary Ap-
pendix 2). Samples were obtained from patients 
enrolled under clinical-trial protocols of St. Jude 
Children’s Research Hospital, the Children’s On-
cology Group, the Eastern Cooperative Oncology 
Group, the Alliance for Clinical Trials in Oncol-
ogy (Cancer and Leukemia Group B), and M.D. 
Anderson Cancer Center. The details of the treat-
ment protocols are provided in Supplementary 
Appendix 2. Patients, parents, or guardians gave 
written informed consent for sample collection 
and research, with assent provided by older chil-
dren and adolescents. The study was approved by 
the St. Jude Institutional Review Board. Data 
from the study have been deposited in the Euro-
pean Genome Phenome archive under accession 
number EGAS00001000654.
Next-Generation Sequencing
A total of 154 patients with Ph-like ALL under-
went detailed genomic analysis, 147 of whom 
underwent one or more of the following types of 
next-generation sequencing: transcriptome se-
quencing (136 patients), whole-genome sequenc-
ing (42), and whole-exome sequencing (12) of 
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tumor and matched remission DNA (Table S1 in 
Supplementary Appendix 1).14 Next-generation 
sequencing was not performed for 7 patients, who 
instead underwent reverse-transcriptase poly-
merase-chain-reaction analysis. Transcriptome 
sequencing was also performed for 160 patients 
with non–Ph-like ALL (Table S3 in Supplemen-
tary Appendix 2). Details of Ph-like ALL classifi-
cation, sequencing, and analysis are provided in 
Supplementary Appendix 2.
Microarray Profiling and Functional  
and Cytogenetic Assays
The details of gene expression and single-nucle-
otide-polymorphism microarray profiling, fluo-
rescence in situ hybridization, cell-line prolifera-
tion and tyrosine kinase inhibitor assays, protein 
expression, and xenograft experiments are pro-
vided in Supplementary Appendix 2.
Statistical Analysis
Associations between categorical variables were 
examined with the use of Fisher’s exact test. As-
sociations between Ph-like ALL status and treat-
ment outcome (event-free survival and overall 
survival) were examined with the use of the 
Kaplan–Meier estimator, with Peto’s estimator 
of standard deviation and the log-rank test, in 
each patient cohort (children, adolescents, and 
young adults).4,15,16 An event was defined as a fail-
ure to achieve remission, a relapse after remis-
sion, or the development of a second malignant 
neoplasm. A multivariable analysis of event-free 
and overall survival was performed with the Cox 
proportional-hazards regression model.17 Analy-
ses were performed with the use of Prism soft-
ware, version 6.0 (GraphPad Software), R software 
(www.r-project.org),18 and SAS software, version 
9.1.2 (SAS Institute).
R esult s
Clinical Characteristics and Outcomes
Overall, 264 of 1725 precursor B-cell ALL cases 
(15.3%) were identified as Ph-like ALL (Table S4 
in Supplementary Appendix 2). The prevalence of 
Ph-like ALL significantly increased with age, from 
10% among children with standard-risk ALL and 
13% among those with high-risk ALL to 21% 
among adolescents with ALL and 27% among 
young adults with ALL (P<0.001 for the compari-
sons of children with adolescents and children 
with young adults). Furthermore, patients with 
Ph-like ALL had higher leukocyte counts at pre-
sentation than did patients with non–Ph-like ALL, 
both overall (106,000 vs. 59,000 per cubic milli-
meter, P<0.001) and in the different age cohorts 
(Table S5 in Supplementary Appendix 2). Ph-like 
ALL was more common among males than among 
females (Table S5 in Supplementary Appendix 2) 
and was associated with elevated levels of minimal 
residual disease at the end of induction therapy in 
the Children’s Oncology Group trials (Table S6 
in Supplementary Appendix 2). Among patients 
with Ph-like ALL, the median (±SD) 5-year event-
free survival rates for children with high-risk ALL, 
adolescents, and young adults was 58.2±5.3%, 
41.0±7.4%, and 24.1±10.5%, respectively, and the 
5-year overall survival rates were 72.8±4.8%, 
65.8±7.1%, and 25.8±9.9% (Fig. 1). Across all age 
groups, these survival rates were inferior to those 
among patients with non–Ph-like ALL (P<0.001 
for both comparisons) (Fig. S2 in Supplementary 
Appendix 2). The presence of Ph-like ALL was an 
independent prognostic factor in all age groups 
(Table S7 in Supplementary Appendix 2).
Identification of Kinase Alterations  
in Ph-like ALL
A total of 123 of 264 patients with Ph-like ALL had 
high CRLF2 expression, with the frequency rang-
ing from 24% among children with standard-risk 
ALL to 60% among adolescents with ALL. Among 
patients with high CRLF2 expression, we identi-
fied P2RY8–CRLF2 in 45 patients and IGH–CRLF2 in 
61 patients; for 17 patients, there was insuffi-
cient material for analysis. Sixty-eight patients 
(55%) with CRLF2 rearrangement had concomi-
tant Janus kinase mutations, most commonly in 
JAK2 (Fig. S3 in Supplementary Appendix 2).
To identify the spectrum of kinase-activating 
alterations in the remaining patients with Ph-like 
ALL, we performed next-generation sequencing in 
30 patients with CRFL2 rearrangement and 124 
patients without CRLF2 rearrangement (Tables S8 
and S9 in Supplementary Appendix 1). The analy-
ses of gene-expression levels from transcriptome 
sequencing recapitulated those from microarray 
expression data, with clustering of Ph-like and 
BCR–ABL1–positive cases (Table S10 in Supple-
mentary Appendix 1 and Fig. S4 and Fig. S5 in 
Supplementary Appendix 2).
Genomic alterations activating kinase signal-
ing were identified in 91% of patients with Ph-
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like ALL and were divided into distinct subgroups 
of kinase and cytokine receptor genes (Fig. 2, 
and Fig. S6 in Supplementary Appendix 2). These 
included fusions predicted to respond to ABL1 
inhibitors (involving ABL1, ABL2, CSF1R, or PDGFRB) 
(12.6% of cases); rearrangements of EPOR (3.9%) 
or JAK2 (7.4%); rearrangements of CRLF2 (49.7%); 
genetic alterations of IL7R, FLT3, SH2B3, JAK1, 
JAK3, TYK2, and IL2RB (shown under “Other 
JAK–STAT” in Fig. 2; 12.6%); Ras pathway muta-
tions, several of which were associated with hy-
podiploidy (4.3%); and uncommon fusions (e.g., 
involving NTRK3 or DGKH; 0.9%). A minority of 
patients (4.8%) were not found to have a kinase-
activating alteration on transcriptome sequenc-
ing analysis, and suitable material for analysis 
was not available for 3.9% of patients. The fre-
quencies of these subgroups varied with age. 
Notably, ABL-class rearrangements were more 
common among children, and JAK2 rearrange-
ments were more frequent among young adults 
(Fig. S7 in Supplementary Appendix 2).
In the transcriptome sequencing analysis, we 
identified 223 gene rearrangements in 116 of 
136 patients (mean, 1.6 per patient; range, 0 to 
12) (Table S11 in Supplementary Appendix 1); 
115 of these were either chimeric in-frame fu-
sions or rearrangements resulting in deregulated 
gene expression. Across the entire cohort, rear-
rangements activating kinase signaling were 
identified in 96 of 154 patients (62%), including 
35 different rearrangements (16 of which were 
recurrent) in 13 kinase, cytokine, or cytokine-
receptor genes: JAK2 (10 fusion partners), ABL1 
(6), PDGFRB (4), ABL2 (3), CRLF2 (2), EPOR (2), 
PTK2B (2), CSF1R (1), DGKH (1), IL2RB (1), NTRK3 
(1), TSLP (1), and TYK2 (1) (Table 1 and Fig. 2, 
and Table S12 in Supplementary Appendix 1 and 
Table S13 in Supplementary Appendix 2). All 
kinase fusions retained an intact tyrosine kinase 
domain (Fig. S8 in Supplementary Appendix 2) 
and were found by means of fluorescence in situ 
hybridization to be present in the predominant 
clone at diagnosis (Fig. S9 in Supplementary Ap-
pendix 2).
Thirty patients with CRLF2 rearrangement were 
studied with the use of transcriptome sequencing 
and whole-genome sequencing (Fig. 2, and Fig. 
S10 in Supplementary Appendix 2). We found ad-
ditional alterations activating JAK–STAT in 5 of 
11 patients who had CRLF2 rearrangement but no 
JAK mutations; these alterations included IL7R 
mutations (4 patients), an FLT3 mutation (1 pa-
tient), and a deletion of SH2B3, which encodes 
the JAK2 negative regulator LNK (1 patient). One 
patient had an IQGAP2–TSLP fusion; this resulted 
in overexpression of TSLP, which encodes thymic 
stromal lymphopoietin, the ligand for CRLF2. 
Figure 1. Kaplan–Meier Estimates of Event-free and Overall Survival  
among Patients with Philadelphia Chromosome–like Acute Lymphoblastic 
Leukemia (Ph-like ALL).
Panel A shows the median (±SD) rates of event‑free survival for young 
adults, adolescents, and high‑risk children with Ph‑like ALL (24.1±10.5%, 
41.0±7.4%, and 58.2±5.3%, respectively). Panel B shows rates of overall 
survival in the three age groups (25.8±9.9%, 65.8±7.1%, and 72.8±4.8%,  
respectively).
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Two patients had fusions that deregulated protein 
tyrosine kinase 2 β (PTK2B, or FAK2). Thus, mul-
tiple kinase-activating lesions are likely to cooper-
ate with CRLF2 rearrangement in leukemogenesis.
Sequence mutations and focal deletions acti-
vating JAK–STAT signaling, including in IL7R, FLT3, 
SH2B3, JAK1, and JAK3, were identified in 31 
patients without CRLF2 rearrangement or other 
kinase fusions. Fifteen patients had alterations 
in the Ras pathway only, including NRAS, KRAS, 
PTPN11, NF1, and BRAF (Fig. 2, and Fig. S11 in 
Supplementary Appendix 2). Eleven patients had 
mutations in multiple genes, with evidence of 
subclonality in 7 of the 8 patients who under-
went whole-genome or whole-exome sequencing 
(Table S14 and Fig. S12 in Supplementary Ap-
pendix 2). Details of non-kinase fusions and 
sequence mutations are provided in the Results 
section of Supplementary Appendix 2.
On analysis of gene-expression data from tran-
scriptome sequencing, patients with ABL-class, 
EPOR, or JAK2 rearrangements clustered sepa-
rately from those with other JAK–STAT or Ras 
pathway alterations (Fig. S13 in Supplementary 
Appendix 2). We also found differences in out-
come between the Ph-like ALL subgroups, with 
patients who had rearrangements of JAK2 or 
EPOR having the worst outcome (Table S15 and 
Fig. S14 in Supplementary Appendix 2).
As previously described,4,5,11 we found a high-
er frequency of IKZF1 alterations (deletion or 
point mutation) among patients with Ph-like 
ALL than among patients with BCR–ABL1–nega-
tive non–Ph-like ALL (166 of 244 [68%] vs. 204 
of 1241 [16%], P<0.001) (Table S16 in Supple-
mentary Appendix 2). IKZF1 alterations were 
more common in patients with Ph-like ALL who 
had kinase fusions (140 of 180 [78%]) than in 
those with a sequence mutation (14 of 43 [33%], 
P<0.001) (Fig. S6 in Supplementary Appendix 2). 
Furthermore, patients with Ph-like ALL who had 
an IKZF1 alteration had inferior median (±SD) 
5-year event-free survival, as compared with pa-
tients who had Ph-like ALL without an IKZF1 
alteration; these survival differences were seen 
in children with high-risk ALL (48.6±7.0 vs. 
71.7±8.0 years, P<0.001) and in young adults 
(18.5±11.8 vs. 42.9±18.7 years, P<0.001) (Fig. S15 
in Supplementary Appendix 2). When IKZF1 al-
terations were considered in combination with 
Kinase Gene
Tyrosine Kinase 
 Inhibitor
Fusion 
 Partners Patients 5′ Genes
number
ABL1 Dasatinib 6 14 ETV6,11 NUP214,11 RCSD1,11 RANBP2,11 SNX2,19 ZMIZ120
ABL2 Dasatinib 3 7 PAG1,* RCSD1,* ZC3HAV1*
CSF1R Dasatinib 1 4 SSBP2*
PDGFRB Dasatinib 4 11 EBF1,11-13 SSBP2,* TNIP1,* ZEB2*
CRLF2 JAK2 inhibitor 2 30 IGH,21 P2RY822
JAK2 JAK2 inhibitor 10 19 ATF7IP,* BCR,11 EBF1,* ETV6,23 PAX5,11 PPFIBP1,* SSBP2,24 
STRN3,11 TERF2,* TPR*
EPOR JAK2 inhibitor 2 9 IGH,11 IGK*
DGKH Unknown 1 1 ZFAND3*
IL2RB JAK1 inhibitor, JAK3  
inhibitor, or both
1 1 MYH9*
NTRK3 Crizotinib 1 1 ETV625-27†
PTK2B FAK inhibitor 2 1 KDM6A,* STAG2*
TSLP JAK2 inhibitor 1 1 IQGAP2*
TYK2 TYK2 inhibitor 1 1 MYB*
*  The gene is a previously unreported fusion partner.
†  ETV6–NTRK3 has been reported in multiple cancers, including congenital fibrosarcoma25,26 and secretory breast carcinoma,27 but it has not 
previously been described in acute lymphoblastic leukemia.28,29
Table 1. Kinase Fusions Identified in Ph-like Acute Lymphoblastic Leukemia.
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mutations in other lymphoid transcription fac-
tors (ETV6, EBF1, ERG, PAX5, and TCF3), 86% of 
patients with Ph-like ALL (209 of 244) were 
found to have alterations affecting lymphoid 
development, as compared with 61% of patients 
with non–Ph-like ALL (762 of 1241, P<0.001).
Activity of Tyrosine Kinase Inhibitors  
in Ph-like ALL
To determine the transforming properties of the 
kinase fusions, we assessed their ability to induce 
cytokine-independent proliferation in mouse in-
terleukin-3–dependent Ba/F3 cells and interleu-
Figure 3. Response to Tyrosine Kinase Inhibitors.
Panel A shows the proliferation of interleukin‑7–dependent primary Arf−/− pre‑B cells expressing the dominant  
negative Ikaros isoform (Ik6) with empty vector, RCSD1–ABL1, RCSD1–ABL2, SSBP2–CSF1R, or PAX5–JAK2 in  
the absence of cytokine. Panel B shows the growth of Arf−/− pre‑B cells in increasing concentrations of dasatinib. 
Panel C shows constitutive phosphorylation of STAT5 and CRKL (pSTAT5 and pCRKL, respectively). Cells expressing 
ABL2, CSF1R, and JAK2 fusions have enhanced STAT5 activation, which is inhibited by dasatinib in RCSD1–ABL2 
and SSBP2–CSF1R and by ruxolitinib in PAX5–JAK2.
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kin-7–dependent Arf−/− pre-B cells30,31 expressing 
the dominant negative isoform of Ikaros, Ik6.6 
Expression of all fusions tested (RCSD1–ABL1, 
RANBP2–ABL1, ZMIZ1–ABL1, RCSD1–ABL2, 
SSBP2–CSF1R, and PAX5–JAK2) conferred cyto-
kine-independent proliferation (Fig. 3A, and Fig. 
S16 in Supplementary Appendix 2). The ABL1, 
ABL2, and CSF1R fusions were sensitive to the 
ABL-class inhibitors imatinib (50% inhibitory 
concentration [IC50], 135 to 900 nM) (data not 
shown) and dasatinib (IC50, 1 to 2 nM), whereas 
PAX5–JAK2 was not sensitive to these agents 
(Fig. 3B). Differences in signaling-pathway acti-
vation between the fusions were observed. All 
fusions activated STAT5, which was inhibited by 
dasatinib in cells expressing ABL1, ABL2, CS-
F1R, or PDGFRB fusions,11 and the JAK2 inhibi-
tor ruxolitinib attenuated phosphorylated STAT5 
in cells expressing PAX5–JAK2. Phosphorylation 
of CRKL, a target of ABL1 and ABL2, was seen 
only in cells expressing these fusions (Fig. 3C). 
Human leukemic cells harboring ATF7IP–JAK2 
or IGH–EPOR were sensitive to ruxolitinib, 
whereas imatinib had no effect (Fig. S17A in 
Supplementary Appendix 2). As reported previ-
ously in studies of other tumor models,32 cells 
expressing ETV6–NTRK3 responded to the ALK 
inhibitor crizotinib (Fig. S17B in Supplementary 
Appendix 2). The efficacy of dasatinib was also 
assessed in a xenograft model of ETV6–ABL1 
ALL in which human leukemic cells were en-
grafted into immunodeficient mice. After 4 
weeks of treatment, percentages of circulating 
human CD45+ cells were significantly reduced 
in the dasatinib-treated mice, as compared with 
vehicle-treated controls (17% vs. 88%, P<0.001), 
as was splenic weight (117 vs. 321 mg, P<0.001) 
(Fig. S17C in Supplementary Appendix 2).
The high frequency of kinase-activating le-
sions in the patients with Ph-like ALL suggests 
that tyrosine kinase inhibitor therapy is likely to 
be effective in such patients, as it is in patients 
with BCR–ABL1–positive ALL.33 To assess this, 
we studied 34 patients with precursor B-cell ALL 
who had high-risk clinical features at diagnosis, 
alterations found on cytogenetic analysis that 
were suggestive of a tyrosine kinase gene rear-
rangement, or a poor response to induction che-
motherapy (Table S17 in Supplementary Appen-
dix 2). Remarkably, 86% of patients (24 of 28) 
who underwent testing with a low-density gene-
expression array34 had Ph-like ALL, and 22 of these 
patients had a targetable kinase fusion involving 
ABL1 (10 patients), ABL2 (3), CRLF2 (3), JAK2 (3), or 
PDGFRB (3). Notably, we identified 4 patients with 
induction failure who had EBF1–PDGFRB. Of the 
12 patients who began receiving tyrosine kinase 
inhibitor therapy, 11 with available follow-up data 
had rapid and sustained responses. Details for 
each patient are provided in the Results section of 
Supplementary Appendix 2.
Discussion
In this study of 1725 children, adolescents, and 
young adults with precursor B-cell ALL, we de-
fined the frequency and poor outcome of Ph-like 
ALL, characterized the genetic landscape of al-
terations activating kinase signaling, and found 
that the majority of patients with Ph-like ALL 
have genetic alterations responsive to Food and 
Drug Administration–approved tyrosine kinase 
inhibitors. Building on the precedent established 
for BCR–ABL1–positive ALL,33 these findings 
provide a strong rationale for testing new thera-
pies to improve the outcome of Ph-like ALL. We 
studied more than 500 adolescents and young 
adults with ALL, for whom treatment outcomes 
are substantially inferior to those of children 
with ALL. The frequency of Ph-like ALL is high-
er than 25% among young adults with ALL. Be-
cause BCR–ABL1–positive ALL represents more 
than 20% of precursor B-cell ALL cases in this 
age group, about half of young adults with pre-
cursor B-cell ALL are candidates for tyrosine 
kinase inhibitor therapy. The frequency of Ph-
like ALL among older adults with ALL is un-
known but merits investigation in view of the 
poor treatment outcome in this age group.
We identified several subgroups of Ph-like 
ALL distinguished by the type of cytokine recep-
tor or kinase alteration that was present. The 
frequencies of CRLF2 rearrangement (47%) and 
concomitant JAK1 or JAK2 mutation (55% among 
patients with CRFL2 rearrangement) in the entire 
cohort are consistent with previous reports,11,35 
with the highest frequency observed in adoles-
cent ALL (60%). Previous reports have shown 
that the JAK2 inhibitor ruxolitinib is active in 
models of ALL with CRLF2 rearrangement, which 
suggests that JAK inhibition may be used in the 
treatment of these high-risk patients.36,37
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The second major subgroup of Ph-like ALL is 
characterized by fusions involving ABL-class ki-
nase genes. Multiple ABL1 and PDGFRB fusions 
and new targets of rearrangement were identified, 
including ABL2 (also known as Abelson-related 
gene, or ARG) and CSF1R (encoding the macro-
phage colony-stimulating factor receptor), which 
are known to respond to the ABL1 inhibitor ima-
tinib.38,39 Importantly, we have shown that pre-B 
cells expressing ABL2 and CSF1R fusions acti-
vate oncogenic signaling pathways and cellular 
proliferation that is potently inhibited by dasat-
inib at concentrations similar to those for BCR–
ABL1, other ABL1 fusions, and EBF1–PDGFRB.11
A striking finding was the high frequency of 
rearrangements activating JAK2, particularly in 
young adults. The PAX5–JAK2 fusion activated 
JAK–STAT signaling and conferred cytokine-inde-
pendent proliferation that was sensitive to rux-
olitinib. We previously identified a single patient 
with Ph-like ALL who had a cryptic insertion of 
EPOR, encoding the erythropoietin receptor, into 
the immunoglobulin heavy-chain locus; the cur-
rent study shows that the insertion of EPOR into 
IGH and IGK is a recurring event in Ph-like ALL. 
Human leukemic cells with EPOR rearrangement 
exhibit activation of JAK–STAT signaling and are 
sensitive to JAK inhibitors ex vivo. Thus, JAK in-
hibition is a widely applicable treatment approach 
in Ph-like ALL.
We also identified distinct subgroups of pa-
tients with Ph-like ALL who had sequence muta-
tions or structural alterations of genes involved 
in JAK–STAT or MAPK signaling. Alteration of 
IKZF1 was less common in such patients than in 
patients with Ph-like ALL who had a kinase rear-
rangement, and rearrangement of transcriptional 
regulators and chromatin modifiers was more 
common (Fig. S20 and Table S21 in Supplemen-
tary Appendix 2). Several patients with Ph-like 
ALL had Ras mutations but no other kinase al-
terations. Currently, direct therapeutic targeting 
of oncogenic Ras mutations is challenging, but 
targeting signaling pathways downstream of Ras 
may be considered.
The event-free and overall survival rates among 
patients with Ph-like ALL were markedly inferior 
to those among patients with non–Ph-like ALL, 
in all age groups studied. Thus, implementation 
of therapy directed against the activated kinase 
is an attractive strategy to improve the outcome 
for these high-risk patients. Although our data 
have highlighted the genetic complexity of Ph-
like ALL, this entity can be rapidly identified with 
a low-density gene-expression array,34 and the 
majority of treatable kinase-activating lesions can 
be identified with the use of conventional mo-
lecular and cytogenetic approaches (Fig. S18 in 
Supplementary Appendix 2). The importance of 
identifying Ph-like ALL is highlighted by recent 
reports of the success of tyrosine kinase inhibi-
tors in the treatment of relapsed or refractory 
EBF1–PDGFRB Ph-like ALL.12,13 Remarkably, most 
patients with ALL who had clinical features sug-
gestive of Ph-like ALL and who were tested pro-
spectively in this study were identified as having 
Ph-like ALL with treatable fusions. Furthermore, 
all patients treated with the relevant tyrosine ki-
nase inhibitor for whom clinical-response data 
were available had rapid and durable responses. 
Together, these findings indicate that Ph-like ALL 
is common, particularly among adolescents and 
young adults, and is associated with a high risk 
of treatment failure. Clinical trials combining 
kinase inhibitors with chemotherapy in patients 
with Ph-like ALL, guided by careful use of screen-
ing and genomic testing, are warranted.
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